engleski

BEAM myeloablative chemotherapy with autologous bone marrow and/or peripheral blood stem cells transplantation in poor risk pretreated malignant lymphoma patients

Autologous bone marrow (ABMT) and peripheral blood stem cells transplantation (PBSCT) rescue is promising method in the treatment of malignant lymphoma patients. It is not clear whether heavily pretreated and poor risk pts. have benefit of this method. From November 1993. to May 1996. 20 heavily pretreated lymphoma pts. received BEAM myeloablative chemotherapy and autologous bone marrow and/or peripheral blood stem cells rescue. Median age was 34 years (range 18-48). Eleven pts. had non-Hodgkin lymphoma and 9 Hodgkin disease. Nineteen of 20 pts. at the moment of BEAM therapy had active disease. Average number of CD34 positive cells was 3.68x10E6/kg and 2.06x10E8/kg MNC. All pts. have been treated with myeloid growth factors (GCSF or GMCSF) in posttransplant period. Median time to assess L>1x10E9/L was 12 days (range 9-18). Platelets recovery (>20x10E9/L) median was 16 days (range 11-30). Average applicated RBC transfusion was 612ml (SD 428.4) and platelets transfusion 20.95 (SD 11.53) doses. Sixteen pts (80%) achieved complete remission and 3 partial remission (15%). Projected DFS at 30 months is 52% and projected overall survival from ABMT at 30 months is 79%. We concluded that BEAM myeloablative chemotherapy with ABMT and/or PBSCT in heavily pretreated malignant lymphoma pts. is effective, safe and can be recomended in heavily pretreated patients with active disease.

transplantation; lymphoma

nije evidentirano